Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today.

According to a release, the study will be conducted as part of a Specialized Program of Research Excellence (SPORE) grant given by the National Cancer Institute.

“While we remain focused on advancing CLR 131 as a therapy for hematologic malignancies, we look forward to seeing the outcomes of the university’s research,” Cellectar Biosciences CEO Jim Caruso said in a statement. “We are grateful for our long-standing relationship with the University of Wisconsin and congratulate them, and in particular, Dr. Paul Harari, chair of human oncology, who oversaw the SPORE grant application.”

CLR 131, which uses iodine-131 as its payload, is currently in a Phase 1 clinical trial for multiple myeloma.